Affichage 1 à 6 des 6 essais cliniques
|
ESSAI CLINIQUE No essai ClinicalTrials.gov ID |
Investigateur(trice) principal(e)
Coordonnateur(rice) |
||
|---|---|---|---|
|
(EN) A Phase 1 Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
LOXO-IDH-20001 NCT04603001  Actif en recrutement
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Leucémie myéloïde aiguë (LMA) Syndrome myélodysplasique |
Dre Sarit Assouline |
|
(EN) An Open-Label Phase 1a/1b Dose Escalation and Expansion Cohort Study of SL-172154 (SIRP?-Fc-CD40L) in Combination With Azacitidine or With Azacitidine and Venetoclax for the Treatment of Subjects With Higher-Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
SL03-OHD-104 NCT05275439 Actif en recrutement
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Leucémie myéloïde aiguë (LMA) Syndrome myélodysplasique |
Dre Sarit Assouline Maria Kluchnyk 514-340-8222 poste 26394 |
|
(EN) Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
GS-US-352-4365 NCT03441113 Actif en recrutement
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Syndrome myélodysplasique |
Dr Jonathan How Judit Kokai 438-888-1582 |
|
(EN) A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
CA055-026 NCT05469737 Actif en recrutement
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Syndrome myélodysplasique |
Dr John Storring Judit Kokai 438-888-1582 |
|
Registre Canadien de la SMD
Registre SMD Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
Syndrome myélodysplasique |
Dr Robert Delage Linda Vallée 418-649-0252 poste 66602 |
|
(EN) A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome
SELECT MDS-1 NCT04797780 Actif en recrutement
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Syndrome myélodysplasique |
Dr John Storring Judit Kokai 438-888-1582 |
Groupe d'étude en oncologie du Québec